Potential Side effects The most common side effects of Tirzepatide include nausea, diarrhea, vomiting, constipation, abdominal (stomach) pain, headache, fatigue, dyspepsia (indigestion), dizziness, abdominal distension, eructation (belching), hypoglycemia (low blood sugar) in patients with type 2 diabetes, flatulence (gas buildup), gastroenteritis (an intestinal infection) and gastroesophageal reflux disease (a type of digestive disorder)
We recommend checking with your insurance provider and discussing financing options with our team
Examples include anticholinergic medications and opioid pain medications (e.g., hydrocodone, morphine) Metabolism and clearance Tirzepatide is metabolized by proteolytic cleavage of the peptide backbone, beta-oxidation of the C20 fatty diacid moiety and amide hydrolysis DOSING Dosage forms Single-dose pen 2.5 mg/0.5 ml 5 mg/0.5 ml 7.5 mg/0.5 ml 10 mg/0.5 ml 12.5 mg/0.5 ml 15 mg/0.5 ml Comes in carton with 4 pens Single-dose vials 2.5 mg/0.5 ml 5 mg/0.5 ml 7.5 mg/0.5 ml 10 mg/0.5 ml 12.5 mg/0.5 ml 15 mg/0.5 ml Kwikpen (each pen contains 4 doses) 4 doses of 2.5 mg: 10 mg/2.4 mL (4.17 mg/mL) 4 doses of 5 mg: 20 mg/2.4 mL (8.33 mg/mL) 4 doses of 7.5 mg: 30 mg/2.4 mL (12.5 mg/mL) 4 doses of 10 mg: 40 mg/2.4 mL (16.7 mg/mL) 4 doses of 12.5 mg: 50 mg/2.4 mL (20.8 mg/mL) 4 doses of 15 mg: 60 mg/2.4 mL (25 mg/mL) Multi-dose vial (each vial contains 4 doses) 4 doses of 2.5 mg/0.6 mL: 10 mg/2.4 mL (4.17 mg/mL) 4 doses of 5 mg/0.6 mL: 20 mg/2.4 mL (8.33 mg/mL) 4 doses of 7.5 mg/0.6 mL: 30 mg/2.4 mL (12.5 mg/mL) 4 doses of 10 mg/0.6 mL: 40 mg/2.4 mL (16.7 mg/mL) 4 doses of 12.5 mg/0.6 mL: 50 mg/2.4 mL (20.8 mg/mL) 4 doses of 15 mg/0.6 mL: 60 mg/2.4 mL (25 mg/mL) Dosing Starting: 2.5 mg subcutaneously once weekly
Additionally, when GLP-1 is administered peripherally, it can affect the central regulation of feeding, impacting our brains perception of hunger and fullness
